Endpoints News· @endpts · X·· 1 小时前精选AI 评分58
AI 导读
MimiVax的胶质母细胞瘤疫苗在2b期试验中未达到主要终点，但在65岁及以下患者中显示出4个月的生存获益。该结果来自Endpoints News的报道。
推荐理由
原文给出2b期未达主要终点但65岁及以下患者有4个月生存获益，读者可据此判断该疫苗的后续开发空间。
正文
MimiVax's glioblastoma vaccine narrowly missed its Phase 2b goal but showed a four-month survival benefit in patients 65 and under. https://endpoints.news/mimivaxs-cancer-vaccine-for-glioblastoma-narrowly-misses-phase-2b-goal/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源：Endpoints News · x.com